{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:27:38Z","timestamp":1792506458998,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ctrv.2016.12.002","type":"journal-article","created":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T13:30:16Z","timestamp":1483104616000},"page":"120-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":228,"special_numbering":"C","title":["Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"53","author":[{"given":"Husam","family":"Abdel-Qadir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josee-Lyne","family":"Ethier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paaladinesh","family":"Thavendiranathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ctrv.2016.12.002_b0005","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2016.12.002_b0010","first-page":"1029","article-title":"Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis","volume":"146","author":"Dvorak","year":"1995","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2016.12.002_b0015","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ahj.2011.10.018","article-title":"Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"163","author":"Steingart","year":"2012","journal-title":"Am Heart J"},{"issue":"15","key":"10.1016\/j.ctrv.2016.12.002_b0020","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ctrv.2016.12.002_b0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"issue":"9911","key":"10.1016\/j.ctrv.2016.12.002_b0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.ctrv.2016.12.002_b0035","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2016.12.002_b0040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"9605","key":"10.1016\/j.ctrv.2016.12.002_b0045","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ctrv.2016.12.002_b0050","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.ctrv.2016.12.002_b0055","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2006.10.5122","article-title":"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer","volume":"25","author":"Heymach","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2016.12.002_b0060","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2010.29.5436","article-title":"Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787\/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.12.002_b0065","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","article-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9630","key":"10.1016\/j.ctrv.2016.12.002_b0070","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0140-6736(08)60661-3","article-title":"Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study","volume":"371","author":"Spano","year":"2008","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.ctrv.2016.12.002_b0075","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ctrv.2016.12.002_b0080","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ctrv.2016.12.002_b0085","unstructured":"Microsoft Excel. In. 2010 ed. Redmond, Washington: Microsoft; 2010."},{"key":"10.1016\/j.ctrv.2016.12.002_b0090","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. In: S HJG, (ed). Version 5.1.0 [updated March 2011]: The Cochrane Collaboration; 2011."},{"key":"10.1016\/j.ctrv.2016.12.002_b0095","unstructured":"Review Manager (RevMan) [Computer program]. In. 5.3 ed. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014."},{"issue":"7305","key":"10.1016\/j.ctrv.2016.12.002_b0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bmj.323.7305.157","article-title":"Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests","volume":"323","author":"Deeks","year":"2001","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.ctrv.2016.12.002_b0105","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2016.12.002_b0110","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1200\/JCO.2009.21.9220","article-title":"Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer","volume":"27","author":"Allegra","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.12.002_b0115","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa1111097","article-title":"Bevacizumab added to neoadjuvant chemotherapy for breast cancer","volume":"366","author":"Bear","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.12.002_b0120","first-page":"125","article-title":"Docetaxel-carboplatin in combination with erlotinib and\/or bevacizumab in patients with non-small cell lung cancer","volume":"6","author":"Boutsikou","year":"2013","journal-title":"Onco Targets Ther"},{"issue":"32","key":"10.1016\/j.ctrv.2016.12.002_b0125","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"29","author":"Brufsky","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2016.12.002_b0130","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2016.12.002_b0135","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(13)70335-8","article-title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","volume":"14","author":"Cameron","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2016.12.002_b0140","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2016.12.002_b0145","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(14)70110-X","article-title":"Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study","volume":"15","author":"Corrie","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2016.12.002_b0150","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","volume":"14","author":"Cunningham","year":"2013","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2016.12.002_b0155","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","article-title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial","volume":"13","author":"de Gramont","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2016.12.002_b0160","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2016.12.002_b0165","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1200\/JCO.2012.44.7912","article-title":"AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent\/metastatic breast cancer","volume":"31","author":"Gianni","year":"2013","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2016.12.002_b0170","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMc1403303","article-title":"Bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2016.12.002_b0175","doi-asserted-by":"crossref","first-page":"682","DOI":"10.5732\/cjc.011.10188","article-title":"Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial","volume":"30","author":"Guan","year":"2011","journal-title":"Chin J Cancer"},{"issue":"9780","key":"10.1016\/j.ctrv.2016.12.002_b0180","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/S0140-6736(11)60545-X","article-title":"Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial","volume":"377","author":"Herbst","year":"2011","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ctrv.2016.12.002_b0185","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ctrv.2016.12.002_b0190","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","article-title":"Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer","volume":"23","author":"Hurwitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.12.002_b0195","first-page":"37","article-title":"Comparative study analyzing survival and safety of bevacizumab\/carboplatin\/paclitaxel versus carboplatin\/docetaxel in initial treatment of metastatic Her-2-negative breast cancer","volume":"5","author":"Kader","year":"2013","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"13","key":"10.1016\/j.ctrv.2016.12.002_b0200","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","article-title":"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401","volume":"30","author":"Kelly","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2016.12.002_b0205","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"28","author":"Kindler","year":"2010","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2016.12.002_b0210","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2016.12.002_b0215","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2016.12.002_b0220","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.ctrv.2016.12.002_b0225","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2016.12.002_b0230","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ctrv.2016.12.002_b0235","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2016.12.002_b0240","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2016.12.002_b0245","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2016.12.002_b0250","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2016.12.002_b0255","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2016.12.002_b0260","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2016.12.002_b0265","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s10120-014-0351-5","article-title":"Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)","volume":"18","author":"Shen","year":"2015","journal-title":"Gastric Cancer"},{"issue":"5\u20136","key":"10.1016\/j.ctrv.2016.12.002_b0270","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000320520","article-title":"Treatment of colorectal cancer with and without bevacizumab: a phase III study","volume":"78","author":"Stathopoulos","year":"2010","journal-title":"Oncology"},{"issue":"7","key":"10.1016\/j.ctrv.2016.12.002_b0275","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/annonc\/mdr571","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306","volume":"23","author":"Stintzing","year":"2012","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2016.12.002_b0280","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","article-title":"Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study","volume":"28","author":"Tebbutt","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2016.12.002_b0285","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ctrv.2016.12.002_b0290","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","article-title":"Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer","volume":"27","author":"Van Cutsem","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.12.002_b0295","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","article-title":"Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer","volume":"366","author":"von Minckwitz","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2016.12.002_b0300","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2016.12.002_b0305","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.12.002_b0310","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.2012.42.1529","article-title":"Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma","volume":"31","author":"Flaherty","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2016.12.002_b0315","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/annonc\/mds135","article-title":"BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer","volume":"23","author":"Goncalves","year":"2012","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2016.12.002_b0320","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","article-title":"Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma","volume":"47","author":"Kudo","year":"2011","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2016.12.002_b0325","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ctrv.2016.12.002_b0330","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2011.39.7646","article-title":"Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine\/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer","volume":"30","author":"Paz-Ares","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2016.12.002_b0335","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2009.26.1321","article-title":"Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer","volume":"28","author":"Scagliotti","year":"2010","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2016.12.002_b0340","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","article-title":"Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma","volume":"27","author":"Hauschild","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2016.12.002_b0345","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10549-010-0788-0","article-title":"Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer","volume":"121","author":"Barrios","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.ctrv.2016.12.002_b0350","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","article-title":"First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study","volume":"30","author":"Bergh","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2016.12.002_b0355","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.2012.45.1930","article-title":"Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial","volume":"31","author":"Carrato","year":"2013","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2016.12.002_b0360","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1200\/JCO.2012.43.3391","article-title":"Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer","volume":"31","author":"Crown","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9544","key":"10.1016\/j.ctrv.2016.12.002_b0365","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctrv.2016.12.002_b0370","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2012.48.5268","article-title":"Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer","volume":"32","author":"Michaelson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2016.12.002_b0375","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ctrv.2016.12.002_b0380","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1200\/JCO.2011.39.2993","article-title":"Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial","volume":"30","author":"Scagliotti","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2016.12.002_b0385","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2011.36.1709","article-title":"Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)","volume":"30","author":"Lee","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2016.12.002_b0390","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","article-title":"Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer","volume":"29","author":"Natale","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2016.12.002_b0395","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2016.12.002_b0400","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1200\/JCO.2010.29.5717","article-title":"Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial","volume":"29","author":"de Boer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2016.12.002_b0405","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","article-title":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial","volume":"11","author":"Herbst","year":"2010","journal-title":"Lancet Oncol"},{"issue":"29","key":"10.1016\/j.ctrv.2016.12.002_b0410","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1200\/JCO.2012.42.6932","article-title":"Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial","volume":"30","author":"Ramlau","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2016.12.002_b0415","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.ejca.2013.04.002","article-title":"Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer","volume":"49","author":"Rougier","year":"2013","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2016.12.002_b0420","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","article-title":"Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial","volume":"14","author":"Tannock","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9944","key":"10.1016\/j.ctrv.2016.12.002_b0425","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ctrv.2016.12.002_b0430","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9829","key":"10.1016\/j.ctrv.2016.12.002_b0435","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ctrv.2016.12.002_b0440","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2010.29.4496","article-title":"Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787\/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma","volume":"29","author":"Hecht","year":"2011","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ctrv.2016.12.002_b0445","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.12.002_b0450","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(11)70004-3","article-title":"Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study","volume":"12","author":"Kindler","year":"2011","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2016.12.002_b0455","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.ctrv.2016.12.002_b0460","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1200\/JCO.2009.25.4482","article-title":"Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599","volume":"28","author":"Dahlberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.12.002_b0465","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1634\/theoncologist.2012-0339","article-title":"Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies","volume":"18","author":"Hurwitz","year":"2013","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.ctrv.2016.12.002_b0470","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1161\/01.RES.0000243989.46006.b9","article-title":"Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis","volume":"99","author":"Ahmad","year":"2006","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.ctrv.2016.12.002_b0475","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1158\/1078-0432.CCR-05-2257","article-title":"Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer","volume":"12","author":"Camp","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2016.12.002_b0480","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1172\/JCI39434","article-title":"Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress","volume":"120","author":"Chintalgattu","year":"2010","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ctrv.2016.12.002_b0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122735","article-title":"Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study","volume":"10","author":"Srikanthan","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ctrv.2016.12.002_b0490","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/S1470-2045(16)00152-2","article-title":"Under-reporting of harm in clinical trials","volume":"17","author":"Seruga","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.12.002_b0495","unstructured":"Black WC, Haggstrom Da Fau-Welch HG, Welch HG. All-cause mortality in randomized trials of cancer screening. (0027\u20138874 (Print))."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216301438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216301438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T07:29:35Z","timestamp":1536132575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216301438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":99,"alternative-id":["S0305737216301438"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.12.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727235613.793555470","asserted-by":"object"}]},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}